Bellicum Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 5 million. Net income was USD 1.23 million compared to net loss of USD 0.887 million a year ago. Basic earnings per share from continuing operations was USD 0.08 compared to basic loss per share from continuing operations of USD 0.18 a year ago. Diluted earnings per share from continuing operations was USD 0.07 compared to diluted loss per share from continuing operations of USD 0.18 a year ago. For the nine months, sales was USD 0.7 million. Revenue was USD 5.7 million. Net loss was USD 12.24 million compared to USD 26.51 million a year ago. Basic loss per share from continuing operations was USD 1.21 compared to USD 5.25 a year ago. Diluted loss per share from continuing operations was USD 1.21 compared to USD 5.25 a year ago.